The Europe human leukocyte antigen (HLA) testing market is expected to grow from US$ 188.49 million in 2022 to US$ 287.77 million by 2028; it is estimated to grow at a CAGR of 7.3% from 2022 to 2028.
The broadening scope of applications of HLA testing makes it mandatory before several medical procedures. The histocompatibility laboratory at TriCore Reference Laboratories provides HLA-related testing for transplantation, platelet donation/blood transfusion, forensic testing, parentage testing, disease association, pharmacogenomics, and transfusion medicine applications; among these, HLA testing is commonly used in disease-association testing. Specific HLA alleles are associated with high or low exposure to various diseases. HLA testing can also be used as a complementary method for diagnosing and assessing hereditary risks. The confirmation of the presence or absence of HLA factors associated with each disease or drug-induced adverse reactions can significantly impact therapeutics. Further, blood transfusion is one of the primary procedures that require HLA testing. Several chronic conditions, surgical procedures, and trauma cases require blood transfusion so that patients can survive without any side effects of low blood levels. Conditions including thalassemia, blood cancer, sickle cell anemia, anemia, and surgical and trauma cases lead to blood loss and require a blood transfusion. Thus, the increasing prevalence of chronic diseases magnifies the demand for blood transfusion, thereby propelling the growth of the HLA testing market.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe human leukocyte antigen (HLA) testing market at a notable CAGR during the forecast period.
The broadening scope of applications of HLA testing makes it mandatory before several medical procedures. The histocompatibility laboratory at TriCore Reference Laboratories provides HLA-related testing for transplantation, platelet donation/blood transfusion, forensic testing, parentage testing, disease association, pharmacogenomics, and transfusion medicine applications; among these, HLA testing is commonly used in disease-association testing. Specific HLA alleles are associated with high or low exposure to various diseases. HLA testing can also be used as a complementary method for diagnosing and assessing hereditary risks. The confirmation of the presence or absence of HLA factors associated with each disease or drug-induced adverse reactions can significantly impact therapeutics. Further, blood transfusion is one of the primary procedures that require HLA testing. Several chronic conditions, surgical procedures, and trauma cases require blood transfusion so that patients can survive without any side effects of low blood levels. Conditions including thalassemia, blood cancer, sickle cell anemia, anemia, and surgical and trauma cases lead to blood loss and require a blood transfusion. Thus, the increasing prevalence of chronic diseases magnifies the demand for blood transfusion, thereby propelling the growth of the HLA testing market.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe human leukocyte antigen (HLA) testing market at a notable CAGR during the forecast period.
Europe Human Leukocyte Antigen (HLA) Testing Market Segmentation
The Europe human leukocyte antigen (HLA) testing market is segmented into product & services, technology, end user, and country.- Based on product & services, the market is segmented into reagents & consumables, instruments, and software & services. In terms of technology, the Europe human leukocyte antigen (HLA) testing market is divided into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment is sub segmented into PCR-based molecular assays, sequencing-based molecular assays, and others.
- Based on end user, the market is divided into independent reference laboratories, hospital and transplant centers, and others.
- Based on country, the Europe human leukocyte antigen (HLA) testing market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe.
Europe Human Leukocyte Antigen (HLA) Testing Market - Companies Mentioned
THERMO FISHER SCIENTIFIC INC.; CareDx; QIAGEN; Illumina, Inc.; Bio-Rad Laboratories, Inc.; F. HOFFMANN-LA ROCHE LTD.; Takara Bio Inc.; Luminex Corporation; Omixon Inc.; Protrans; and CeGaT GmbH are among the major companies operating in the Europe human leukocyte antigen (HLA) testing market.Table of Contents
1. Introduction
3. Research Methodology
4. Europe Human Leukocyte Antigen (HLA) Testing Market - Market Landscape
5. Europe Human Leukocyte Antigen (HLA) Testing Market - Key Market Dynamics
6. Europe Human Leukocyte Antigen (HLA) Testing Market -Analysis
7. Europe Human Leukocyte Antigen (HLA) Testing Market Revenue and Forecast to 2028 - by Product and Services
8. Europe Human Leukocyte Antigen (HLA) Testing Market Revenue and Forecast to 2028- by Technology
9. Europe Human Leukocyte Antigen (HLA) Testing Market Revenue and Forecast to 2028- by End User
10. Europe Human Leukocyte Antigen (HLA) Testing Market Revenue and Forecast to 2028- by Country
11. Europe Human Leukocyte Antigen (HLA) Testing Market - Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- THERMO FISHER SCIENTIFIC INC.
- CareDx
- QIAGEN
- Illumina, Inc.
- Bio-Rad Laboratories, Inc.
- F. HOFFMANN-LA ROCHE LTD.
- Takara Bio Inc.
- Luminex Corporation
- Omixon Inc.
- Protrans
- CeGaT GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 166 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 188.49 Million |
| Forecasted Market Value ( USD | $ 287.77 Million |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Europe |
